Featured Publications
Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes
Kotlyar A, Seifer D. Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive Biology And Endocrinology 2023, 21: 70. PMID: 37528417, PMCID: PMC10391774, DOI: 10.1186/s12958-023-01120-7.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeOvarian hyperstimulation syndromeOvarian stimulationStimulation protocolFrozen embryo transfer cyclesVitamin D repletionGnRH agonist triggerVitamin D levelsEmbryo transfer cyclesOvarian stimulation protocolsAntagonist cyclesHyperstimulation syndromeHypertensive disordersIVF cyclesPCOS patientsAgonist triggerOvarian syndromeOocyte yieldD levelsImproved outcomesPregnancy rateCommon causeIVF performanceTherapeutic courseInfertile couples
2020
High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology
Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reproductive Biology And Endocrinology 2020, 18: 20. PMID: 32156287, PMCID: PMC7065318, DOI: 10.1186/s12958-020-00581-4.Peer-Reviewed Original ResearchConceptsLive birth rateLower live birth ratesHigh AMH groupAMH groupPCOS womenHigh AMHAMH concentrationsFirst fresh IVF/ICSI cycleBirth rateFresh IVF/ICSI cyclesGreater clinical pregnancy ratesSerum antimullerian hormone (AMH) levelsIVF/ICSI cyclesAntimullerian hormone levelsClinical pregnancy rateControlled ovarian stimulationRetrospective cohort studySerum AMH levelsPolycystic ovarian syndromeSerum AMH concentrationsLive birth outcomesNumber of embryosAMH levelsGonadotropin doseOvarian stimulation
2019
Chapter 25 The Role of Antimullerian Hormone in Assisted Reproduction
Tal R, Seifer D. Chapter 25 The Role of Antimullerian Hormone in Assisted Reproduction. 2019, 403-414. DOI: 10.1016/b978-0-12-813209-8.00025-x.ChaptersAntimullerian hormoneOvarian responseControlled ovarian stimulationOnset of menopausePrimordial follicle poolInformative biochemical markersOvarian stimulationOvarian reserveFertility preservationAbnormal folliculogenesisFollicle poolClinical utilityParacrine regulatorSensitive markerStimulation protocolChronologic ageOvarian folliclesGranulosa cellsBiochemical markersReproductive agingReproductive medicineInverse correlationAssisted reproductionReproductive technologiesClinical application
2018
Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility
Butts SF, Seifer DB, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Krawetz SA, Santoro N, Zhang H, Diamond MP, Legro RS, Network E. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 104: 369-378. PMID: 30085176, PMCID: PMC6300410, DOI: 10.1210/jc.2018-00750.Peer-Reviewed Original ResearchConceptsVitamin D deficiencyPolycystic ovary syndromeD deficiencyEarly pregnancy lossOvarian stimulationUnexplained infertilityLive birthsPregnancy lossDiagnosis of PCOSMultiple Intrauterine GestationsOvarian stimulation outcomesRetrospective cohort studyInvestigation of womenBanked seraPPCOS IICohort studyIntrauterine gestationOvary syndromeInfertile womenInfertility diagnosisPregnant subjectsElevated riskImportant treatmentReproductive outcomesTrial data
2017
Ovarian reserve testing: a user’s guide
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. American Journal Of Obstetrics And Gynecology 2017, 217: 129-140. PMID: 28235465, DOI: 10.1016/j.ajog.2017.02.027.Peer-Reviewed Original ResearchConceptsOvarian reserve testingOvarian reserve testsOvarian reserveAntimüllerian hormoneDay 3 follicle-stimulating hormonePolycystic ovary syndromeFemale cancer patientsFollicle-stimulating hormoneFertility treatment optionsSelection of treatmentAntral follicular countAge-specific valuesGood predictive valueComplex clinical phenomenonOvarian hyperstimulationOvarian stimulationOvary syndromeGonadotoxic therapyTreatment optionsCancer patientsPoor responseReproductive ageFollicular countReproductive endocrinologistsTreatment protocol
2015
Assessing ovarian response: antral follicle count versus anti-Müllerian hormone
Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproductive BioMedicine Online 2015, 31: 486-496. PMID: 26283017, DOI: 10.1016/j.rbmo.2015.06.015.Peer-Reviewed Original ResearchConceptsAntral follicle countAnti-Müllerian hormoneAMH levelsOvarian reserveFollicle countOvarian responseFollicle numberPredictive valueSerum anti-Müllerian hormoneGood predictive valuePersonalization of treatmentGold standard biomarkerOvarian stimulationExogenous gonadotrophinsMenstrual cyclePoor responseHormone biomarkersOocyte numberUltrasound biomarkersBiomarkersAmerican SocietyGood responseSame ageHormoneStimulation
2014
Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changesSuccessful Same‐Cycle Blastocyst Transfer following Laparoscopic Ovarian Detorsion: A Report of Two Cases and Literature Review
Irani M, Tal R, Seifer DB, Grazi RV. Successful Same‐Cycle Blastocyst Transfer following Laparoscopic Ovarian Detorsion: A Report of Two Cases and Literature Review. Case Reports In Obstetrics And Gynecology 2014, 2014: 806378. PMID: 24864219, PMCID: PMC4020476, DOI: 10.1155/2014/806378.Peer-Reviewed Original ResearchOvarian torsionEmbryo transferOocyte retrievalFavorable pregnancy outcomeLaparoscopic ovarian detorsionOvarian detorsionLaparoscopic evaluationOvarian stimulationPregnancy outcomesFertilization cyclesInfertility patientsPregnancy chancesSuccessful pregnancyBlastocyst transferEgg retrievalClinical dilemmaOptimal timingDetorsionPatientsConcurrent cyclesSuch casesLiterature reviewPregnancyIVFCasesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation. Vascular Cell 2013, 5: 18. PMID: 24156373, PMCID: PMC3895756, DOI: 10.1186/2045-824x-5-18.Peer-Reviewed Original ResearchPolycystic ovarian syndromeAng-2 levelsAng-1 levelsPCOS womenNumber of oocytesAng-2Ovarian stimulationRetrieval dayAngiopoietin-2Follicular fluidAng-1Angiopoietin-1Serum Ang-1 levelsSerum Ang-2 levelsAng-1/AngSerum Ang-1Prospective cohort studyOvarian hyperstimulationOvarian syndromeCohort studyOvarian functionCapillary leakageFF levelsDay 3Time pointsAngiopoietin-2 is increased in follicular fluid of polycystic ovarian syndrome (PCOS) women during controlled ovarian stimulation and correlates with number of oocytes retrieved
Tal R, Seifer D, Shohat-Tal A, Malter H, Grazi R. Angiopoietin-2 is increased in follicular fluid of polycystic ovarian syndrome (PCOS) women during controlled ovarian stimulation and correlates with number of oocytes retrieved. Fertility And Sterility 2013, 100: s360. DOI: 10.1016/j.fertnstert.2013.07.851.Peer-Reviewed Original ResearchTransforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome
2012
Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation
Tal R, Seifer D, Shohat-Tal A, Grazi R, Malter H. Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation. Fertility And Sterility 2012, 98: s84. DOI: 10.1016/j.fertnstert.2012.07.304.Peer-Reviewed Original ResearchHigh frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers
Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, Broekmans F, Baker VL. High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertility And Sterility 2012, 98: 1037-1042. PMID: 22771028, DOI: 10.1016/j.fertnstert.2012.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAnti-Mullerian HormoneChemistry, ClinicalEstradiolFemaleFertilityFollicle Stimulating Hormone, HumanHumansMenstrual CycleMiddle AgedOocytesOvulation InductionPredictive Value of TestsPrognosisReference StandardsReproductive MedicineRetrospective StudiesUnited StatesYoung AdultConceptsYears of ageFSH valuesSerum AMHAntimüllerian hormoneAMH valuesFertility centerCut pointsDay 2Clinical discordanceMenstrual cycle day 2Follicle-stimulating hormone levelsCycle day 2Reference laboratoryFollicle-stimulating hormoneLarger patient populationSingle reference laboratoryFrequency of discordanceAge-dependent fashionClinical cut pointsSame serum samplesOvarian stimulationPatient populationAMH testingMenstrual cycleHormone levels
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
2000
Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle
Dzik A, Lambert-Messerlian G, Izzo V, Soares J, Pinotti J, Seifer D. Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. Fertility And Sterility 2000, 74: 1114-1117. PMID: 11119736, DOI: 10.1016/s0015-0282(00)01627-7.Peer-Reviewed Original ResearchConceptsInhibin B levelsInhibin B serum levelsB levelsInhibin B responsesSubsequent IVF cycleLevels 24 hoursAcademic clinical practiceGood responsePg/mLGonadotropin challengeBaseline serumInhibin BIVF cyclesOvarian stimulationOocyte retrievalOvarian reserveFertilization cyclesOvarian responseSerum levelsPoor responseOdds ratioMAIN OUTCOMEClinical practiceCorresponding oddsPg/
1997
The impact of hydrosalpinx on successful pregnancy in tubal factor infertility treated by in vitro fertilization
Blazar A, Hogan J, Seifer D, Frishman G, Wheeler C, Haning R. The impact of hydrosalpinx on successful pregnancy in tubal factor infertility treated by in vitro fertilization. Fertility And Sterility 1997, 67: 517-520. PMID: 9091340, DOI: 10.1016/s0015-0282(97)80079-9.Peer-Reviewed Original ResearchConceptsTubal factor infertilityTubal diseaseFactor infertilityPregnancy rateCycle cancellation rateSuccess of IVFNumber of oocytesNumber of embryosHydrosalpinx groupRoutine salpingectomyOvarian stimulationOngoing pregnancyImplantation rateSuccessful pregnancyHydrosalpinxMAIN OUTCOMECancellation ratePatientsOocyte fertilizationInfertilityIVFIVF facilityPregnancyMore cyclesFertilization rate
1996
Autologous granulosa cell coculture demonstrates zygote suppression of granulosa cell steroidogenesis**Presented in part at the 51st Annual Meeting of the American Society for Reproductive Medicine. Seattle, Washington, October 7 to 12, 1995.††Supported in part by Physician Scientist Award (AG00566 [D.B.S.] and R01HD31894 [A.L.S.]) from the National Institutes of Health, National Institute on Aging, Bethesda, Maryland.
Seifer D, Freeman M, Gardiner A, Hill G, Schneyer A, Vanderhyden B. Autologous granulosa cell coculture demonstrates zygote suppression of granulosa cell steroidogenesis**Presented in part at the 51st Annual Meeting of the American Society for Reproductive Medicine. Seattle, Washington, October 7 to 12, 1995.††Supported in part by Physician Scientist Award (AG00566 [D.B.S.] and R01HD31894 [A.L.S.]) from the National Institutes of Health, National Institute on Aging, Bethesda, Maryland. Fertility And Sterility 1996, 66: 425-429. PMID: 8751742, DOI: 10.1016/s0015-0282(16)58513-6.Peer-Reviewed Original ResearchConceptsLuteinized granulosa cellsGranulosa cellsStandard IVF-ET treatment cycleIVF-ET treatment cyclesTwo-pronuclear embryosGranulosa cell steroidogenesisTwo-pronuclear zygotesNational InstituteVitro Fertilization UnitProduction of E2Steroid hormone productionPituitary desensitizationOvarian stimulationFollicular aspiratesCell steroidogenesisFertilization unitTreatment cyclesHormone productionCell coculturesReproductive medicineP productionAmerican SocietyAcademic research environmentE2Human embryos